Antibodies to modified human igf-1/e peptides
AssigneeNovartis AG
InventorsMara Fornaro, John Xu, Yuan Gao, Rainer Hillenbrand, Francois Legay, Daniela Stoellner
Life of this patent
Estimating the term…
Abstract
High-specificity antibodies can distinguish between modified (e.g, hIGF-1/Ea 3mut) and endogenous wild-type human IGF-1 proteins. These antibodies have little or no cross-reactivity with hIGF-1 or hIGF-2. They also have little or no cross-reactivity with rodent IGF-1 or IGF-2. The antibodies can be used in pharmacokinetic (PK)/pharamcodynamic (PD) assessments of IGF-1/E peptides that have been administered to humans or animals. A sandwich ELISA assay, using the antibody of the invention as a capture antibody, can quantify the mutant IGF-1/E proteins in samples.
Claims22
An antibody that binds immunospecifically to peptide GPTLCGAELV (SEQ ID NO:
- 1) but does not bind immunospecifically to peptide GPETLCGAELV (SEQ ID NO:
- 2).
An antibody that binds immunospecifically to peptide PAKSAVRAQR (SEQ ID NO:
- 6) but does not bind immunospecifically to peptide PTKAARSIRAQR (SEQ ID NO:
- 7).
An antibody selected from the group consisting of QC1, QC2, QQ2, QQ5 and QQ6.
An isolated polypeptide comprising the sequence GPTLCGAELV (SEQ ID NO:
- 1), CPAKSAVRAQR (SEQ ID NO:
- 5) or PAKSAVRAQR (SEQ ID NO:
- 6).
(canceled)
(canceled)
Dependencies are inferred from the claim text.